Abstract |
In order to induce a therapeutic T lymphocyte response, recombinant viral vaccines are designed to target professional antigen-presenting cells (APC) such as dendritic cells (DC). A key requirement for their use in humans is safe and efficient gene delivery. The present study assesses third-generation lentivectors with respect to their ability to transduce human and mouse DC and to induce antigen-specific CD8+ T-cell responses. We demonstrate that third-generation lentivectors transduce DC with a superior efficiency compared to adenovectors. The transfer of DC transduced with a recombinant lentivector encoding an antigenic epitope resulted in a strong specific CD8+ T-cell response in mice. The occurrence of lower proportions of nonspecifically activated CD8+ cells suggests a lower antivector immunity of lentivector compared to adenovector. Thus, lentivectors, in addition to their promise for gene therapy of brain disorders might also be suitable for immunotherapy.
|
Authors | Christoph Esslinger, Pedro Romero, H Robson MacDonald |
Journal | Human gene therapy
(Hum Gene Ther)
Vol. 13
Issue 9
Pg. 1091-100
(Jun 10 2002)
ISSN: 1043-0342 [Print] United States |
PMID | 12067442
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Epitopes, T-Lymphocyte
- Interferon-gamma
|
Topics |
- Animals
- CD8-Positive T-Lymphocytes
(immunology)
- Cells, Cultured
- Dendritic Cells
(metabolism)
- Epitopes, T-Lymphocyte
(genetics, immunology)
- Genetic Vectors
(genetics, metabolism)
- HIV-1
(genetics)
- Humans
- Interferon-gamma
(metabolism)
- Lentivirus
(genetics, metabolism)
- Mice
- Mice, Transgenic
- Phenotype
- T-Lymphocytes
(immunology)
- Transduction, Genetic
|